|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Sarcoma Subtype** | **Total**N=105 | **1=Breast Angiosarcoma**N = 54 (51.4%) | **2=Osteosarcoma**N = 12(11.4%) | **3=Soft-Tissue Sarcoma\***N = 39(37.1%) | ***P* Value** |
| **Surgery**  | YesNo | 4113 | 111 | 363 | C: 0.07 |
| **Surgical Margins**  | R0 | 38 | 8 | 24 | C: 0.017 |
|  | R1 | 1 | 3 | 11 |  |
|  | R2 | 2 | 0 | 1 |  |
|  | R0 R1/2 | 38 3 | 8 2 | 24 12 |  |
| **Grade (Unknown/UNK =52)** | 1 | 3 | 0 | 6 | C: 0.025 |
|  | 2 | 6 | 4 | 9 |  |
|  | 3 | 8 | 6 | 11 |  |
| **Max Diameter (cm)** | Median(range) | N = 51/544 (0.8 – 17.5) | N = 11/124.27 (1-8.4) | N = 35/397.5 (1.8 – 23.5) | W: 0.004 |
| **Radiation** | Neoadjuvant | 2 | 0 | 14 | C: <.0001 |
|  | Adjuvant | 11 | 2 | 5 |  |
|  | Palliative | 6 | 1 | 5 |  |
|  | None | 35 | 9 | 15 |  |
|  | YesNo | 1935 | 39 | 2415 | C: 0.015 |
| **RT Dose (Gy)** | Median (range) | N = 19 / 1944 (6.6 – 60) | N = 3 / 339 (30 – 59.4) | N = 24/2444 (1.1 – 60) | W: 0.73 |
| **RT Fractions** | Median (range) | N = 19/1928 (5 – 48) | N = 3 / 313 (10-33) | N = 24/2425 (1– 50) | W: 0.6 |
| **Chemo** | YesNo | 2925 | 75 | 1128 | C: 0.03 |
| **Neoadjuvant chemotherapy (NACT)** | YesNo | 1811 | 52 | 46 | C: 0.35 |
| **Chemo agent** | Gemcitabine | 0 | 0 | 2 | C: <.0001 |
|  | Paclitaxel | 26 | 0 | 0 |  |
|  | Doxorubicin | 2 | 1 | 1 |  |
|  | Doxorubicin/Ifosfamide  | 0 | 0 | 6 |  |
|  | Doxorubicin/Cisplatin +/- Methotrexate | 1 | 6 | 0 |  |
|  | Gemcitabine/Docetaxel | 0 | 0 | 1 |  |
| **Response to NACT** | PD | 4 | 2 | 1 | C: 0.54 |
|  | SD | 2 | 2 | 1 |  |
|  | PR | 8 | 1 | 2 |  |
|  | CR | 4 | 0 | 0 |  |
| **Recurrence**  | YesNo | 2133 | 57 | 1722 | C: 0.9 |
| **Outcome** | NED | 21 | 4 | 14 | C: 0.47C: <.0001 (all) |
|  | Alive with disease | 9 | 2 | 5 |  |
|  | Deceased | 24 | 6 | 20 |  |

**Table 2. Clinico-pathologic characteristics and treatment modalities by RIS subtype**